Shimizu Hiromichi, Suzuki Kohei, Watanabe Mamoru, Okamoto Ryuichi
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Endoscopy, Tokyo Medical and Dental University, Tokyo, Japan.
Intest Res. 2019 Jul;17(3):311-316. doi: 10.5217/ir.2019.00043. Epub 2019 Jul 25.
Inflammatory bowel disease (IBD) is an idiopathic, multi-etiological disease characterized by inflammation and mucosal destruction of the gastrointestinal tract. Despite the remarkable advance in immunomodulating therapies, there still remains a certain population of patients who are refractory to conventional as well as biologic therapies and fail to achieve mucosal healing. To improve the prognosis of those patients, at least 2 types of stem cells have been tested for their potential therapeutic use. Transplantation of hematopoietic stem cells or mesenchymal stem cells have been tested in several clinical studies, but their beneficial effect still remains controversial. In this review, we would like to overview the recent clinical challenges of stem cell-based therapies in IBD and also introduce our new therapeutic plan of intestinal stem cell transplantation for IBD, based on our ex vivo intestinal organoid culture technique.
炎症性肠病(IBD)是一种特发性、多病因疾病,其特征为胃肠道炎症和黏膜破坏。尽管免疫调节疗法取得了显著进展,但仍有一定比例的患者对传统疗法和生物疗法均无反应,无法实现黏膜愈合。为改善这些患者的预后,至少两种类型的干细胞已被测试其潜在治疗用途。造血干细胞或间充质干细胞移植已在多项临床研究中进行测试,但其有益效果仍存在争议。在本综述中,我们将概述基于干细胞疗法在IBD中的近期临床挑战,并基于我们的体外肠道类器官培养技术,介绍我们针对IBD的肠道干细胞移植新治疗方案。